Form 4: Akari Therapeutics Director Acquires Shares and Warrants in Private Placement

Robert Bazemore, a director of Akari Therapeutics Plc, acquired American Depositary Shares (ADS) and warrants in a private placement on March 6, 2025.

Summary

• On March 6, 2025, Robert Bazemore, a director of Akari Therapeutics Plc, acquired 44,642 American Depositary Shares (ADS) and accompanying Series A and Series B warrants.
• The warrants allow Bazemore to purchase up to 89,284 additional ADS.
• The purchase was made through a private placement by Akari Therapeutics pursuant to a Securities Purchase Agreement dated February 27, 2025.
• The combined purchase price was $1.12 per ADS and accompanying warrants.
• Each ADS represents 2,000 Ordinary Shares of Akari Therapeutics with a par value of $0.0001 per share.
• Bazemore also has granted Samir R. Patel and Torsten Hombeck power of attorney to handle securities filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director purchasing shares, which can be seen as a positive, but it's not overwhelmingly so.

Positives

• A director's investment in the company could be seen as a positive signal.

Industry Context

Form 4 filings are standard disclosures for insiders buying or selling company stock, providing transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for company insiders, such as directors, officers, and principal stockholders, to report transactions in their company's securities.
• These filings are publicly available and allow investors to track insider activity, which can provide insights into management's perspective on the company's prospects.
• Similar filings are made by insiders at companies like Amgen, Biogen, and Gilead Sciences, reflecting their transactions in company stock.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive signal.

Key Dates